There are syndromes that are associated with obesity, including …
leptin deficiency, Prader–Willi syndrome, and Lawrence–Moon–Biedl syndrome
Clinical Criteria for Diagnosing Metabolic Syndrome
3 of the following:
… used to treat human immunodeficiency virus (HIV) infection can induce metabolic syndrome secondary to insulin resistance
Protease inhibitors (Indinavir and Lopinavir/ritonavir)
Metabolic syndrome is resolved by bariatric surgery in over …% of patients who achieve the expected weight loss
95
Inflammatory processes appear to play an important role in the metabolic syndrome. Adipose tissue has two major functions: storage and release of … and secretion of proteins required for endocrine and autocrine regulation of energy metabolism.
Adipocytes exert their metabolic effects by release of …, whose release is enhanced by the presence of … .
Visceral adipose tissue has been identified as an important source of proinflammatory cytokines such as … , as well as anti-inflammatory cytokines such as … .
energy-rich fatty acids
free fatty acids
catecholamines, release of glucocorticoids, increased beta-receptor agonist activity, and reduction of lipid storage mediated by insulin
tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)
adiponectin
Increased levels of proinflammatory cytokines likely contribute to the etiology of … primarily by obstructing insulin signaling and contributing to downregulation of peroxisomal proliferator-activated receptor-γ, which are fundamentally important regulators of adipocyte differentiation and control.
insulin resistance
Proteins such as …, which are produced primarily by adipocytes, are classified as adipokines
leptin and adiponectin
Explain the role of leptin in the physiopathology of obesity
Although leptin is primarily involved in appetite control, its immunologic effects include protection of T lymphocytes from apoptosis and regulation of T-cell activation and proliferation. Reduced leptin levels may increase appetite and slow metabolism, but may also increase susceptibility to the toxicity of proinflammatory stimuli, such as endotoxin and TNF-α. Elevated leptin levels are proinflammatory, and this likely plays an important role in the progression of heart disease and diabetes, especially in obese patients
Serum levels of adiponectin correlate with … and … [do/do not] rise in obesity.
Significantly … [increased/reduced] adiponectin levels are found in patients having type 2 diabetes.
Adiponectin reduces both … production and activity. It also inhibits … production.
insulin sensitivity
do not
reduced
TNF-α
IL-6
… , an adipokine that induces insulin resistance, is induced by endotoxin and cytokines.
… acts at the cellular level to upregulate production of proinflammatory cytokines, most likely through the … pathway.
It appears to present a molecular link between metabolic signaling, inflammatory processes, and the development of … disease.
Its levels have been associated with inflammatory markers apparently independent of … in humans.
Resistin
Resistin
nuclear factor κB (NFκB)
cardiovascular
BMI
An obstructive apneic event is defined universally as …
the complete cessation of airflow during breathing lasting 10 seconds or longer despite maintenance of neuromuscular ventilatory effort
The definition of an obstructive hypopneic event may vary depending on the criteria being used for scoring. The Centers for Medicare and Medicaid Services (CMS) defines a hypopneic event as … as opposed to the American Academy of Sleep Medicine (AASM), which accepts a …
the partial reduction of airflow of 30% or more lasting at least 10 seconds, accompanied by a decrease of at least 4% in the oxygen saturation (SpO2)
3% drop in SpO2 or a terminal cortical arousal.
The severity of obstructive sleep apnea/hypopnea syndrome (OSAHS) is arbitrarily defined, but recommendations for disease classification are as follows:
Mild Disease: AHI of 5 to 15 events per hour
Moderate Disease: AHI of 15 to 30 events per hour
Severe Disease: AHI of greater than 30 events per hour
Numerous studies have confirmed that … is the greatest risk factor for OSAHS, with about …% of patients (up to …% of males and up to …% of females) with OSAHS being …
obesity
70
80
50
obese
Describe the STOP-Bang Questionnaire
1) Snoring: Do you snore loudly (loud enough to be heard through closed doors)?
2) Tired: Do you often feel tired, fatigued, or sleepy during daytime?
3) Observed apnea: Has anyone observed you stop breathing during your sleep?
4) Pressure: Do you have or are you being treated for high blood pressure?
5) BMI more than 35kg/m2?
6) Age over 50 years old?
7) Neck circumference >40cm?
8) Gender: Male?
High risk of OSA: Yes to 3 or more questions.
Low risk of OSA: Yes to 2 or fewer questions.
Levels of many different inflammatory mediators, including … are increased in patients with OSAHS
IL-6, high-sensitivity C-reactive protein (hs-CRP), leptin, TNF-α, IL-1, reactive oxygen species, and adhesion molecules, such as intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1),
… [adaptive/native] immune responses act aberrantly in obese individuals.
… cell cytotoxic activity is depressed with obesity, as are plasma levels of cytokines such as … , and … known to regulate … cell function
Native
Natural killer (NK)
IL-12, IL-18
interferon-γ
NK
… , which selectively inhibits intestinal cholesterol absorption, can be combined with statin therapy to further reduce LDL cholesterol by 15% to 20%.
… effectively decrease triglyceride levels while increasing HDL cholesterol. They lower LDL cholesterol levels mildly, but when combined with statin therapy, they may increase
the risk of myopathy.
… decrease triglyceride levels and improve insulin resistance in patients with metabolic syndrome. They are often used in combination therapy with other classes of the hypolipidemic drugs.
… is highly effective in raising HDL cholesterol levels in patients with metabolic syndrome. It decreases the concentration of small, dense LDL particles and also lowers serum levels of lipoprotein (a)
Ezetimibe
Fibrates
Omega-3 fatty acids
Nicotinic acid
The AHA recommends that low-dose aspirin be used as a form of primary prevention in patients with metabolic syndrome whose 10-year risk for cardiovascular disease is …
10% or greater as determined by Framingham risk scoring
Currently five drugs have FDA approval to be prescribed for long-term use for the specific indication of weight loss in adults: …
orlistat (Xenical, Alli),
phentermine–topiramate (Qsymia),
naltrexone–bupropion (Contrave),
liraglutide (Saxenda),
semaglutide (Wegovy).
Orlistat mechanism of action and particularities
Orlistat, a lipase inhibitor, reversibly binds to lipase and prevents both absorption and digestion of certain dietary fats. Because orlistat also interferes with the absorption of fat-soluble vitamins, patients using this drug need to supplement fatsoluble vitamins A, D, E, and K. It has significant GI side effects including diarrhea, steatorrhea, flatulence, fecal incontinence, and oily rectal discharge
Phentermine–topiramate mechanism of action and particularities
Phentermine–topiramate, an adrenergic reuptake inhibitor combined with an anticonvulsant, augments adrenergic signaling within the central nervous system and peripheral tissues. Phentermine decreases appetite and food intake and increases resting metabolic rate to promote weight loss. Its side effects include drowsiness, dry mouth, difficulty sleeping, tingling of the extremities, and constipation.
Naltrexone–bupropion mechanism of action and particularities
Naltrexone–bupropion is a combination of an opioid receptor antagonist with a dopamine and norepinephrine reuptake inhibitor. Naltrexone is used to treat alcohol and drug dependence while bupropion is often used for depression and smoking cessation. This combination of medication is postulated to curb hunger and help control cravings by regulating feelings of pleasure when eating. Common side effects of naltrexone–bupropion include GI distress, dry mouth, hypertension, tachycardia, and possible increased risk of suicidal thoughts and actions
Liraglutide and semaglutide mechanism pf action and particularities
Liraglutide and semaglutide are synthetic analogues of human glucagon-like peptide-1(GLP-1) and act as a GLP-1 receptor agonist. They both increase the production of insulin, inhibit glucagon secretion, and reduce food intake by lowering appetite and slowing down digestion in the stomach. Side effects can include GI distress, fatigue, and pancreatitis